ReviewTherapeutics and clinical risk management2018

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL.

Matthew H Forsberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.